Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial

doi:10.19852/j.cnki.jtcm.20221006.001

Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (1): 140-145.DOI: 10.19852/j.cnki.jtcm.20221006.001

• Original articles • Previous Articles Next Articles

Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial

AN Xuedong¹, MAO Lina², XIA Ping³, SU Wen⁴, WANG Beibei⁵, KOU Leiya⁵, ZHANG Zequan⁸, QI Meng⁵, HU Song⁶, CHEN Jing⁵, LI Xiujuan⁷, LIU Jinwei⁶, ZHOU Juan³, QIAO Jie⁸, LUO Dan⁵, LUO Guangwei⁵, YAN Youqin⁹, YANG Guiping¹¹, DONG Dandan⁹, ZHOU Wei¹⁰, TAO Junxiu¹², JIN De¹, TONG Xiaolin¹³(), WEI Li¹⁴()

1 Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2 Department of Traditional Chinese Medicine, Wuhan No.1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
3 Department of Orthopedics, Wuhan No. 1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
4 Department of Paediatrics, Wuhan No.1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
5 Department of Respiratory and Critical Care Medicine, Wuhan No.1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
6 Department of Pharmacy, Wuhan No. 1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
7 Department of Geriatrics, Wuhan No. 1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China
8 College of Traditional Chinese Medicine, Hubei University of Traditional Chinese Medicine, Wuhan 430060, China
9 Department of Infectious Diseases, Wuhan No.7 Hospital, Wuhan 430071, China
10 Department of Gastroenterology, Wuhan No.7 Hospital, Wuhan 430071, China
11 Department of Gastroenterology, Xiaogan Traditional Chinese Medicine Hospital, Xiaogan 432100, China
12 Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China
13 Institute of Metabolic Diseases, Guang’an Men Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
14 Department of Critical Care Medicine, Wuhan No.1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China

Received:2021-11-19 Accepted:2022-02-19 Online:2023-02-15 Published:2023-01-10
Contact: TONG Xiaolin,WEI Li
About author:WEI Li, Department of Critical Care Medicine, Wuhan No.1 Hospital (Wuhan Integrated TCM and Western Medicine Hospital), Wuhan 430022, China, e_weili@126.com. Telephone:+86-10-88001402; +86-27-85860666
TONG Xiaolin, Institute of Metabolic Diseases, Guang’an Men Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China, tongxiaolin@vip.163.com;
Supported by:
Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Improve Symptoms Associated with Pulmonary Heart Function during Recovery from COVID-19 (II)(2020ZYLCYJ08-4)

Abstract

AN Xuedong, MAO Lina, XIA Ping, SU Wen, WANG Beibei, KOU Leiya, ZHANG Zequan, QI Meng, HU Song, CHEN Jing, LI Xiujuan, LIU Jinwei, ZHOU Juan, QIAO Jie, LUO Dan, LUO Guangwei, YAN Youqin, YANG Guiping, DONG Dandan, ZHOU Wei, TAO Junxiu, JIN De, TONG Xiaolin, WEI Li. Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial[J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 140-145.

Figures/Tables 7

References 15

1	Vellingiri B, Jayaramayya K, Iyer M, et al. COVID-19: a promising cure for the global panic. Sci Total Environ 2020; 725: 138277.
2	Ahn DG, Shin HJ, Kim MH, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 2020; 30: 313-24.
3	Tong XL, Li X, Zhao L, et al. Discussion on Traditional Chinese Medicine prevention and treatment strategies of coronavirus disease 2019 (COVID-19) from the perspective of “Cold-dampness Pestilence”. Zhong Yi Za Zhi 2020; 61: 465-70+553.
4	National Health Commission of the People’s Republic of China. Update on COVID-19 as of 24:00, 16 October (Chin). Published October 16, 2020. Accessed March 4, 2020 http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.shtml.
5	Chen GH, Su W, Yang J, et al. Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study. Front Med 2020; 14: 752-9.
6	Turcu RP, Polich GR, Steere HK, Schneider JC, Borg-Stein J, Silver JK. Letter to the editor on "rehabilitation following critical illness in people with COVID-19 Infection". Am J Phys Med Rehabil 2020; 99: 787-8.
7	Tang XL, Liu L, Xiao W Y, et al. Research on the mechanism of Shengmai decoction against arrhythmia diseases based on molecular simulation. Shi Zhen Guo Yi Guo Yao 2019; 30: 2552-5.
8	Zhang Q. Effects of ShengMai Yin on pulmonary function, blood gas analysis and serum levels of TGF-β₁, IL-6 and TNF-α in patients with COPD complicated by pulmonary interstitial fibrosis. Xian Dai Zhong Xi Yi Jie He Za Zhi 2020; 29: 534-7.
9	National Health Commission of the People’s Republic of China. Notice on the issuance of the fifth edition of the Diagnosis and Treatment Guideline for COVID-19 (Trial Version) (Chin). Published March 4, 2020.Accessed March 4, 2020 http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.shtml.
10	Mo WL, Chai CZ, Kou JP, Yan YQ, Yu BY. Sheng-Mai-San attenuates contractile dysfunction and structural damage induced by chronic intermittent hypoxia in mice. Chin J Nat Med 2015; 13: 743-50.
11	Zhang YC, Chen RM, Lu BJ, Rong YZ. Effect of Shengmai injection on cardiac function and inflammatory reaction in patients with acute coronary syndrome. Chin J Integr Med 2008; 14: 107-10.
12	Ma S, Li X, Dong L, Zhu J, Zhang H, Jia Y. Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats. BMC Complement Altern Med 2016; 16: 61.
13	Zheng H, Chen Y, Chen J, Kwong J, Xiong W. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst Rev 2011: CD005052.
14	Gong YB, Luo ZG, Gao SH, et al. Cross-sectional study on the relationship between formulas and syndromes of type 2 diabetes based on association rules. Zhong Yi Za Zhi 2010; 51: 64-7.
15	Huang X, Duan X, Wang K, Wu J, Zhang X. Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: a systematic review and Meta-analysis. Complement Ther Med 2019; 43: 140-7. DOI PMID

Item		Total (n = 200)	Trial group (n = 100)	Control group (n = 100)	P value
Age (years)		54 (46-62)	54 (46-62)	55 (48-63)	0.271
Sex [n (%)]	Men	72 (36.00)	41 (41.00)	31 (31.00)	0.141
Sex [n (%)]	Women	128 (64.00)	59 (59.00)	69 (69.00)	0.141
Body mass index (kg/m2)		22.8 (21.2-25.00)	22.8 (21.2-25.00)	23.0 (21.1-25.2)	0.660
Smoking history [n (%)]	Yes	15 (7.50)	6 (6.00)	9 (9.00)	0.421
Smoking history [n (%)]	No	185 (92.50)	94 (94.00)	91 (91.00)	0.421
Drinking history [n (%)]	Yes	17 (8.50)	8 (8.00)	9 (9.00)	0.800
Drinking history [n (%)]	No	183 (91.50)	92 (92.00)	91 (91.00)	0.800
Body temperature (℃)		36.3 (36.2-36.5)	36.3 (36.2-36.5)	36.3 (36.2-36.5)	0.734
Systolic pressure [n (%)]	90-139	156 (78.00)	80 (80.00)	76 (76.00)	0.546
	140-159	39 (18.5)	19 (19.00)	20 (20.00)
	160-179	4 (2.00)	1 (1.00)	3 (3.00)
	≥180	1 (0.50)	0 (0.00)	1 (1.00)
Diastolic pressure [n (%)]	<60	3 (1.50)	2 (2.00)	1 (1.00)	0.678
	60-89	166 (83.00)	85 (85.00)	81 (81.00)
	90-99	23 (11.50)	9 (9.00)	14 (14.00)
	100-109	8 (4.00)	4 (4.00)	4 (4.00)
	≥110	0 (0.00)	0 (0.00)	0 (0.00)
Respiratory rate (%)		19 (18-20)	19 (18-20)	19 (18-19)	0.961
Heart rate (times)		80 (75-90)	80 (75-90)	80 (75-89)	0.931
COVID-19 severity grading [n (%)]	Mild	54 (27.00)	30 (30.00)	24 (24.00)	0.374
	Ordinary	125 (62.50)	58 (58.00)	67 (67.00)
	Severe	20 (10.00)	12 (12.00)	8 (8.00)
	Critical	1 (0.50)	0 (0.00)	1 (1.00)
Imaging characteristics [n (%)]	Normal	47 (23.50)	26 (26.00)	21 (21.00)	0.404
Imaging characteristics [n (%)]	Abnormal	153 (76.50)	74 (74.00)	79 (79.00)	0.404
Blood routine examination [n (%)]	Normal	194 (97.00)	95 (95.00)	99 (99.00)	0.097
Blood routine examination [n (%)]	Abnormal	6 (3.00)	5 (5.00)	1 (1.00)	0.097
Comorbidity [n (%)]	With	47 (23.50)	20 (20.00)	27 (27.00)	0.243
Comorbidity [n (%)]	Without	153 (76.50)	80 (80.00)	73 (73.00)	0.243

Item		Total (n = 200)	Trial group (n = 100)	Control group (n = 100)	P value
Age (years)		54 (46-62)	54 (46-62)	55 (48-63)	0.271
Sex [n (%)]	Men	72 (36.00)	41 (41.00)	31 (31.00)	0.141
Sex [n (%)]	Women	128 (64.00)	59 (59.00)	69 (69.00)	0.141
Body mass index (kg/m2)		22.8 (21.2-25.00)	22.8 (21.2-25.00)	23.0 (21.1-25.2)	0.660
Smoking history [n (%)]	Yes	15 (7.50)	6 (6.00)	9 (9.00)	0.421
Smoking history [n (%)]	No	185 (92.50)	94 (94.00)	91 (91.00)	0.421
Drinking history [n (%)]	Yes	17 (8.50)	8 (8.00)	9 (9.00)	0.800
Drinking history [n (%)]	No	183 (91.50)	92 (92.00)	91 (91.00)	0.800
Body temperature (℃)		36.3 (36.2-36.5)	36.3 (36.2-36.5)	36.3 (36.2-36.5)	0.734
Systolic pressure [n (%)]	90-139	156 (78.00)	80 (80.00)	76 (76.00)	0.546
	140-159	39 (18.5)	19 (19.00)	20 (20.00)
	160-179	4 (2.00)	1 (1.00)	3 (3.00)
	≥180	1 (0.50)	0 (0.00)	1 (1.00)
Diastolic pressure [n (%)]	<60	3 (1.50)	2 (2.00)	1 (1.00)	0.678
	60-89	166 (83.00)	85 (85.00)	81 (81.00)
	90-99	23 (11.50)	9 (9.00)	14 (14.00)
	100-109	8 (4.00)	4 (4.00)	4 (4.00)
	≥110	0 (0.00)	0 (0.00)	0 (0.00)
Respiratory rate (%)		19 (18-20)	19 (18-20)	19 (18-19)	0.961
Heart rate (times)		80 (75-90)	80 (75-90)	80 (75-89)	0.931
COVID-19 severity grading [n (%)]	Mild	54 (27.00)	30 (30.00)	24 (24.00)	0.374
	Ordinary	125 (62.50)	58 (58.00)	67 (67.00)
	Severe	20 (10.00)	12 (12.00)	8 (8.00)
	Critical	1 (0.50)	0 (0.00)	1 (1.00)
Imaging characteristics [n (%)]	Normal	47 (23.50)	26 (26.00)	21 (21.00)	0.404
Imaging characteristics [n (%)]	Abnormal	153 (76.50)	74 (74.00)	79 (79.00)	0.404
Blood routine examination [n (%)]	Normal	194 (97.00)	95 (95.00)	99 (99.00)	0.097
Blood routine examination [n (%)]	Abnormal	6 (3.00)	5 (5.00)	1 (1.00)	0.097
Comorbidity [n (%)]	With	47 (23.50)	20 (20.00)	27 (27.00)	0.243
Comorbidity [n (%)]	Without	153 (76.50)	80 (80.00)	73 (73.00)	0.243

Serial number	Drug number	Group	Reason	Enter the FAS	Enter the PPS	Enter the SS
1	001028	Trial	Stop drug because of adverse events on the 11th day	Yes	No	Yes
2	002009	Trial	Stop drug because of adverse events to 3 d	Yes	No	Yes
3	003006	Control	4 d because of poor curative effect to quit the test	Yes	No	Yes
4	001048	Control	Medication compliance 71.42%, < 80%	Yes	No	Yes
5	001043	Control	Medication compliance 71.42%, < 80%	Yes	No	Yes
6	002057	Control	Cured and discharged less than 2 weeks, contrary to inclusion criteria	Yes	No	Yes
7	002119	Control	Medication compliance 57.14%, < 80%	Yes	No	Yes
8	002063	Control	Medication compliance 42.85%, < 80%	Yes	No	Yes

Serial number	Drug number	Group	Reason	Enter the FAS	Enter the PPS	Enter the SS
1	001028	Trial	Stop drug because of adverse events on the 11th day	Yes	No	Yes
2	002009	Trial	Stop drug because of adverse events to 3 d	Yes	No	Yes
3	003006	Control	4 d because of poor curative effect to quit the test	Yes	No	Yes
4	001048	Control	Medication compliance 71.42%, < 80%	Yes	No	Yes
5	001043	Control	Medication compliance 71.42%, < 80%	Yes	No	Yes
6	002057	Control	Cured and discharged less than 2 weeks, contrary to inclusion criteria	Yes	No	Yes
7	002119	Control	Medication compliance 57.14%, < 80%	Yes	No	Yes
8	002063	Control	Medication compliance 42.85%, < 80%	Yes	No	Yes

Symptoms	Control group (n = 100 )	Trial group (n = 100 )	P value
Shortness of breath	3.8±2.0	2.8±2.2	0.773
Hidrosis	2.5±2.6	2.8±2.7	0.384
Chest distress	4.0±2.3	4.4±2.0	0.231
Palpitation	3.2±2.5	3.0±2.5	0.558
Dry cough	1.9±2.4	1.4±2.2	0.162

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us

Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 15

Related Articles 15

Recommended Articles

Metrics

Comments

Time	Symptom	Efficacy	Trial group (n = 98)	Control group (n = 94)	P value
1 week	Shortness of breath	Effective	45.45	47.19	0.817
	Shortness of breath	Cure	4.76	4.60	0.492
	Hidrosis	Effective	45.76	52.38	0.465
	Hidrosis	Cure	14.55	11.48	0.564
	Chest distress	Effective	50.00	56.52	0.383
	Chest distress	Cure	3.75	3.33	0.384
	Palpitation	Effective	56.00	55.52	0.764
	Palpitation	Cure	4.44	7.14	0.793
	Dry cough	Effective	38.00	47.22	0.392
	Dry cough	Cure	4.44	7.14	0.293
2 week	Shortness of breath	Effective	71.43	68.97	0.725
	Shortness of breath	Cure	16.67	12.64	0.457
	Hidrosis	Effective	74.55	68.85	0.497
	Hidrosis	Cure	12.73	24.59	0.104
	Chest distress	Effective	75.00	55.56	0.008
	Chest distress	Cure	22.50	17.78	0.442
	Palpitation	Effective	72.46	74.29	0.808
	Palpitation	Cure	37.68	28.57	0.254
	Dry cough	Effective	82.98	80.00	0.762
	Dry cough	Cure	57.45	42.86	0.191

Indicator	Time		Control group (n = 100)	Trial group (n = 100)	P value
Heart rate	1 week	A new exception to the baseline	3 (3.00)	2 (2.00)	0.651
Heart rate	1 week	No exception to the baseline	97 (97.00)	98 (98.00)	0.651
Systolic blood pressure	1 week	A new exception to the baseline No exception to the baseline	8 (8.00) 92 (92.00)	13 (13.00) 87 (87.00)	0.249
Diastolic blood pressure	1 week	A new exception to the baseline	9 (9.00)	11 (11.00)	0.637
Diastolic blood pressure	1 week	No exception to the baseline	91 (91.00)	89 (89.00)	0.637
Heart rate	2 week	A new exception to the baseline	1 (1.00)	0 (0.00)	0.316
Heart rate	2 week	No exception to the baseline	99 (99.00)	100 (100.00)	0.316
Systolic blood pressure	2 week	A new exception to the baseline	10 (10.00)	9 (9.00)	0.809
Systolic blood pressure	2 week	No exception to the baseline	90 (90.00)	91 (91.00)	0.809
Diastolic blood pressure	2 week	A new exception to the baseline	7 (7.00)	13 (13.00)	0.157
Diastolic blood pressure	2 week	No exception to the baseline	93 (93.00)	87 (87.00)	0.157

[1]	FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071.
[2]	SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639.
[3]	ZHANG Yuehong, SHAO Xianzhi, ZHAO Qianlong, ZHAN Hualong, ZHANG Jianhua, DU Sisi, CHEN Jing, LIU Yingfang, ZHOU Haiwang, CHEN Xinsheng, HONG Ying, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness of Xiangsha Liujun pills (香砂六君丸) on decreased digestive function in convalescent patients of coronavirus disease 2019: a randomized, double blind, placebo controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 552-558.
[4]	XU Guihua, CHEN Feifei, ZHANG Wei, WU Yingen, CHEN Xiaorong, SHI Kehua, WANG Zhenwei, SHI Miaoyan, ZHANG Xing, LU Yunfei, YUAN Weian, LYU Hua, CHEN Xuan. Effectiveness of Traditional Chinese Medicine on coronavirus disease 2019 in 92 patients: a retrospective study [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 582-587.
[5]	YANG Cunqing, LIAN Fengmei, YANG Guiping, HUANG Yufeng, ZHANG Shuangbin, WANG Jianghua, ZHOU Jing, GUO Dongqing, SHEN Chuanyun, YE Tiansong, FU Aojie, LI Xiaoli, CHEN Le, ZHANG Huifeng, TU Qiyin, WANG Ying, YANG Wenzhe, TONG Xiaolin, BA Yuanming. Effectiveness of Xiaoyao capsule (逍遥丸) on sleep disorders and mood disturbance in patients in recovery from coronavirus disease 2019: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 343-351.
[6]	GAO Xiumei, WANG Chenyan, NI Yong, ZHANG Huiling. Clinical effect of acupuncture along fascia, meridians, and nerves combined with ultrasound-guided paravertebral nerve block in the treatment of postherpetic neuralgia: a randomized parallel-controlled study [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 359-364.
[7]	ZHANG Yuehong, DONG Dandan, YAN Youqin, ZHANG Hao, WANG Guangli, ZHOU Wei, LI Wei, QIU Li, LI Tingming, LIU Quan, XIA Ping, MAO Lina, YANG Danlin, YANG Lu, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness and safety of Jinshuibao capsules (金水宝胶囊) in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 134-139.
[8]	LI Ximeng, KANG Yuan, LI Wenjing, LIU Zhuangzhuang, XU Zhenlu, ZHANG Xiaoyu, CAI Runlan, GAO Yuan, QI Yun. Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 51-59.
[9]	ZHU Qingguang, ZHANG Shuaipan, LI Jingxian, SUN Wuquan, CHENG Wei, ZHAN Chao, CHENG Yanbin, FANG Lei, FANG Min. Effectiveness of Liu-zi-jue exercise on coronavirus disease 2019 in the patients: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 997-10053.
[10]	AN Xuedong, ZHANG Qing, TAO Junxiu, LI Li, CHEN Yun, LI Kejian, HE Jing, LIU Ru, GUO Juan, ZHANG Jia, ZHU Hui, LIAN Fengmei, LI Xiaodong. Shugan Jieyu capsule (舒肝解郁胶囊) improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 803-809.
[11]	CHEN Huang, SHI Lushaobo, SHI Zengping, XIA Yi, WANG Dong. Factors influencing physician's behavioral intention to use Traditional Chinese Medicine to treat coronavirus disease 2019 based on the theory of planned behavior [J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 633-6400.
[12]	ZHAO Yufeng, PANG Huaxin, Lü Lanting, ZHOU Pei, WANG Kaining, CAI Shengxing, ZHANG Huifeng, LI Kun. Risk assessment and analysis of Traditional Chinese Medicine intervention in coronavirus disease [J]. Journal of Traditional Chinese Medicine, 2022, 42(3): 472-478.
[13]	XIA Wenguang, ZHENG Chanjuan, ZHANG Jixian, HUANG Min, LI Qinglin, DUAN Can, LI Zhengliang, FAN Cunyu, ZOU Yilong, XU Bo, YANG Fengwen, LIU Qingquan. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine [J]. Journal of Traditional Chinese Medicine, 2022, 42(2): 234-241.
[14]	YAN Shixing, Lü Yi, LIU Ziqing, REN Meng, HE Haiyang, XIAO Li, GUO Feng, PENG Miao, LI Xiaoxia, WANG Yong, XU Xi, YANG Tao, SHAO Zuoyu, HUANG Jingjing, XIAO Mingzhong. Mining intrinsic information of convalescent patients after suffering coronavirus disease 2019 in Wuhan [J]. Journal of Traditional Chinese Medicine, 2022, 42(2): 279-288.
[15]	LI Li, AN Xuedong, ZHANG Qing, TAO Junxiu, HE Jing, CHEN Yun, LI Kejian, LIU Ru, GUO Juan, ZHANG Hao, TONG Xiaolin, BA Yuanming. Shumian capsule(舒眠胶囊) improves symptoms of sleep mood disorder in convalescent patients of Corona Virus Disease 2019 [J]. Journal of Traditional Chinese Medicine, 2021, 41(6): 974-981.